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The pharmaceutical industry is increasingly joining chemoinformatics in the search for the development 
of new drugs to be used in the treatment of diseases. These computational studies have the advantage of 
being less expensive and optimize the study time, and thus the interest in this area is increasing. Among 
the techniques used is the development of multitarget directed ligands (MTDLs), which has become an 
ascending technique, mainly due to the improvement in the quality of treatment involving several drugs. 
Multitarget therapy is more effective than traditional drug therapy that emphasizes maximum selectivity 
for a single target. In this review a multitarget drug survey was carried out as a promising strategy in 
several important diseases: neglected diseases, neurodegenerative diseases, AIDS, and cancer. In addition, 
we discuss Computer-Aided Drug Design (CADD) techniques as a tool in the projection of multitarget 
compounds against these diseases.
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INTRODUCTION
According to the definition of Richard Morphy, 
the multitarget drugs are defined as compounds that are 
designed to modulate multiple targets of relevance to a 
disease, with the overall goal of enhancing efficacy and/
or improving safety (Morphy, Rankovic, 2005).
The multitarget drug is a key that can open multiple 
locks. Research into a multifunctional compound can 
follow two paths: comprehensive experimental analyses, 
or by first using computer aided rational drug design; 
followed by screening and identifying potential targets, 
optimizing the research, and avoiding higher expenses 
(Yildirim et al., 2007; Lavecchia, Giovanni, 2013). 
Furthermore, multitarget therapy is more effective than 
traditional drug therapy, which emphasizes maximum 
selectivity for a single target. By interacting with 
different targets, complex diseases of multifactorial 
origin are treated with greater effectiveness and in less 
time. Requiring smaller doses for simultaneous targets, 
multitarget therapies also feature lower toxicity and 
reduced side effects (Morphy, Rankovic, 2005).
However, despite the therapeutic potential of 
multitarget compounds, there are challenges regarding 
their discovery and development. Like the difficulty in 
choosing the right combination of targets involved in 
the diseases of interest, necessitating the understanding 
of target-disease action mechanism relationships and 
adverse effects profile, as well as establishing similar 
levels of action intensity for each target and design the 
molecules to avoid interactions with unwanted targets. 
In addition, it should be noted that only one part of the 
molecule can interact with each of the proposed targets, 
and the other part may become an obstacle to the binding 
event, reducing binding action due to enteric and entropy-
based approaches. In this way, to include some degree of 
flexibility in the molecule can help the pharmacological 
characteristics, however, taking care that there is not an 
excess of flexibility, thus interfering negatively in the 
binding affinity (due to the unfavorable entropic loss 
associated with the binding event) or the bioavailability 
of the drug (Jayaraman et al., 2013), being these critical 
factors to be reflected in the planning of these compounds 
(Decker, 2007;  Ramsay et al., 2018).
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The term “one-target-one-disease” has been growing 
during the discovery of new drugs in recent years, mainly 
due to the complexity of some diseases (Bawa et al., 
2016). Among these drugs, another term is “cocktail 
therapy,” which is based on the combination of several 
drugs in clinical practice, in which these various drugs 
can act on several targets and may have synergistic effects 
in treatment. However, these effects may be hindered by 
disadvantages, which involve the pharmacokinetics of 
these compounds, the various side effects that each drug 
can cause, and the possible interactions between the drugs 
administered (Lin et al., 2017; Li et al., 2016).
Due to problems encountered in the use of these 
techniques, a new approach has emerged called multi-
target-directed ligands (MTDLs) that is being used as a 
way to overcome undesirable clinical effects. As a goal, 
this technique is based on the principle “one-compound-
multiple-targets,” that is, the use of a compound that can 
interact with more than one target, guaranteeing greater 
effectiveness and fewer side effects (Morphy, 2012). 
Using computer-aided drug design (CADD), in 
silico methods were developed to facilitate the screening of 
new compounds with multitarget characteristics. Several 
studies have been reported in the literature addressing 
these methods targeting multiple targets (Ma et al., 2010). 
Lately, many such techniques are key tools in multi-target 
drug discovery (MTDD) to find drug leads that at the same 
time interact with multiple target agents. These techniques 
are categorized into fragment-based and combinatorial 
approaches. Conventionally, for each individual target 
and to find virtual hits, combinatorial approaches perform 
parallel searches to determine which hit interacts with 
more than one target. Because of such inquires, novel 
drugs for targets to use for one disease and/or to decrease 
the resistance, have been found (Abdolmaleki, Ghasemi, 
Ghasemi, 2017).
Design and development of a single chemical entity 
that acts simultaneously at multiple molecular targets is 
gaining major consideration in drug discovery. On the 
other hand, several multi-target molecular entities are 
currently emerging from the drug discovery programs, 
and some of these agents are now in clinical use for the 
management of various hematologic malignancies and 
solid tumors (Gentile et al., 2017).
Most different FDA approved multikinase inhibitors 
for use of cancer therapy as Vandetanib (a), Regorafenib 
(b), Ponatinib (c), Crizotinib (d) Cabozantinib (e) in 
Figure 1 cited in review of Gentile et al. (2017). 
Some others examples as Lapatinib (Tykerb) 
Figure 2 (a) is a reversible, ATP-competitive inhibitor of 
the HER2 and EGFR tyrosine kinases (Konecny et al., 
2006), and Duvelisib (Figure 2 (b)), a novel oral dual 
inhibitor of PI3K-δ, γ, is clinically active in advanced 
hematologic malignancies (Flinn et al., 2018). 
This review discusses studies that used in silico tools 
to discover new compounds that have potential multitarget 
activity for several diseases, among neglected diseases, 
neurodegenerative diseases, and different types of cancer.
NEGLECTED DISEASES (ND)
Neglected Tropical Diseases (NTDs) is a diverse 
group of communicable diseases that prevail in tropical 
and subtropical conditions in 149 countries (WHO, 2018d). 
NDs are generally associated with poverty, induced by 
inequalities and neglect by governments in a way that 
generates disinterest in the pharmaceutical industry. 
They reach the lives of one billion people worldwide and 
threaten the health of millions of people (WHO, 2010), 
causing 170,000 deaths a year (Watts, 2017). They are 
diseases caused by infectious agents such as viruses, 
bacteria, protozoa and helminths, prevalent in developing 
and underdeveloped countries (de Souza, 2010). They 
entail profound financial costs to the population, such as 
visceral leishmaniasis, whose costs exceed 20% of total 
annual household expenditures for 30% of households 
in Ethiopia, about a quarter of households in Bangladesh 
and Sudan, and 14% of households in India (Watts, 2017).
There is a difficulty in investing in research for this 
type of disease, which makes it increasingly difficult to 
combat and prevent it. Therefore, it is necessary to study 
the therapy of neglected diseases, and the computational 
studies are becoming more and more associated in this 
field, due to their low cost and the flexibility of the 
techniques used. Chemoinformatics plays a very important 
role in the discovery of new multitarget agents, which may 
be more effective and have low toxicity, to assist in the 
treatment of these diseases.
LEISHMANIASIS
A disease caused by parasites of the genus 
Leishmania, which infects about 15 million people 
around the world (Loriá-Cervera, Andrade-Narváez, 2014; 
Reithinger et al., 2007), with 200.000-400.000 new cases 
of visceral leishmaniasis annually (DNDi, 2018b), as 
well as 90% of the cases of mucocutaneous leishmaniasis 
occurring in Bolivia, Brazil and Peru (WHO, 2018c). 
For treatment, the antimonial pentavelente is still used as 
the medicine of first choice, or the amphotericina B and 
pentamidine like drugs as a second choice. These are toxic, 
for some we still do not know the mechanism of action 
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FIGURE 1 - Vandetanib (a), Regorafenib (b), Ponatinib (c), Crizotinib (d) Cabozantinib (e).
FIGURE 2 - Lapatinib (a), Duvelisib (b). 
involved, besides the fact that some species are already 
resistant (Arboleda et al., 2013; Sundar et al., 2002). 
Therefore, there is a need for research investigating new 
compounds that are effective in the therapy of this disease 
by acting on more than one target in the parasite and that 
is not toxic to the patient.
Studies by Trossini, Maltarollo and Schmidt 
(2014), evaluated by Hologram QSAR models (HQSAR) 
multitargets compounds. From the series of 40 active 
sesquiterpene lactones against some species of parasites, 
including Leishmania donovani, PLS models generated 
using different latent variables were evaluated through 
cross-validation (exit-one-out and leave-n-out) and 
validation external. Of the five best HQSAR models, the 
highest value of Q2 LOO was 0.78 and R2ext of 0.944, 
being the coefficients for L. donovani (Table I).
Another study, by Bernal, Coy-Barrera (2014), 
used a set of 123 sesquiterpenes with leishmanicidal 
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activity, which was subdivided into sesquiterpene-
coumarins, agarofurans, drimanes, pseudoguaianolides, 
germacranolides, guaianolides, eudesmanolides, and 
xanthanolides. Molecular docking was then performed 
in order to verify some multitarget compound. Four 
target enzymes of two species of Leishmania were used: 
pteridine reductase (PTR1, PDB: 2QHX), cysteine 
synthase (LmCS, PDB: 4AIR), trypanosintetase (TryS, 
PDB: 2VOB) from L. major and N-myristoyl transferase 
(NMT, PDB: 2WUU) from L. donovani for a better 
understanding of the mode of binding of these compounds.
Thus, it was possible to verify that two sesquiterpene 
coumarins (Figure 3) bind more easily to PTR1 and TryS, 
and some xanthanolides (Figure 4) also showed higher 
affinity for PTR1 and LmCS binding, for inhibition 
purposes. These results are promising for structural 
optimization studies aiming at a better activity.
Among other classes of natural products, a study 
was conducted by Lorenzo et al. (2016) with alkaloids, 
where the potential activity of azaphenanthrene alkaloids 
eupolaramine, imbiline 1, imbiline 4, sampangine, 
3-methoxyisampangine, and 4-methoxyampampine of A. 
dolichocarpa, as well as a database with 142 aporphinal 
alkaloids isolated from Annonaceae, using virtual screening 
(VS) through the search of active molecules against 
Leishmania donovani. These were classified according 
to pIC50 values to develop and validate a model using the 
Random Forest algorithm. Using Volsurf + program v. 1.0.7, 
128 molecular descriptors were generated, which served 
as input data in the Knime program (see 2.10.0), for the 
consequent generation of the model. 
In addition, based on reports from the literature on 
a multitarget model of computational chemistry to predict 
the results of experimental tests for Leishmania (García 
et al., 2011), the molecular docking study was carried out 
using five enzymes different from L. donovani extracted 
from the PDB. From this analysis, it was suggested 
that aporphynic alkaloid (xyloguyelline) (Figure 5) be 
analyzed as a molecule with potential multitarget for the 
treatment of leishmaniasis, presenting activity against 
five strategic enzymes for treatment with a probability of 
activity of 60%.
Chagas disease: Trypanossoma cruzi
Also known as American trypanosomiasis, caused 
by the protozoan Trypanosoma cruzi. The main vector 
TABLE I - Model data generated from Leishmania donovani
HQSAR Models
Ldon
Fdist A/C/Ch/DA
Fsize 4–7 atoms
HL 83
PC 5
N 25
q2LOO 0.775
SEV 0.279
q2CV 0.753 ± 0.02
r2 0.972
SEE 0.098
r2test 0.944
Fdist: fragment distinction; Fsize: fragment size; HL: 
hologram length; PC: number of PLS principal components; 
N: number of compounds of training set; SEV: standard error 
of validation; SEE: standard error of estimation.
FIGURE 3 - Sesquiterpene coumarins.
FIGURE 4 - Xanthanolide sesquiterpenes.
FIGURE 5 - Xyloguyelline.
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involved in the transmission of the parasite to humans is 
a triatomine bug, also known as a ‘kissing bug’, and can 
be transmitted through blood transfusion, transplantation 
of organs, as well as congenital and oral transmissions. 
About 6-8 million people are infected and approximately 
12,000 deaths occur each year. Less than 1% of infected 
persons have access to current diagnosis and treatment, 
with emergency treatment being indicated for anyone 
during the acute phase and for those in whom the infection 
has been reactivated (immunosuppression), in which case 
the probability of success in the treatment is almost 100%. 
The drugs used for treatment are benznidazole (first-line 
treatment in most countries) and nifurtimox (WHO, 2018a; 
DNDi, 2018a).
One of the enzymes validated in the study of 
promising targets for the treatment of Chagas disease 
is the triosephosphate isomerase (TIM), of which its 
existing inhibitors have low interactions. For this reason, 
Aguilera et al. (2016) reported the study of derivatives 
diarylideneketones (Figure 6) in antitrypanosomal activity, 
with in vitro and IC50 in the range of 86 nM, without 
having negative effects on the mammalian enzyme. In 
addition to this activity, inhibition of 31% for the cruzain 
enzyme was also reported. Molecular docking studies were 
also performed with the compounds, from which it was 
possible to predict the target interactions with the study 
compounds, characterizing the diarylideneketones as a 
new class of compounds with a dual-target effect.
New studies aiming at the antitrypanosomal activity 
of hybrid derivatives quinone–coumarin (Figure 7) were 
performed by Belluti et al. (2014). In their study, they 
showed inhibition of the enzymes glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and trypanothione 
reductase (TR), with IC50 of 5.4 μM and 2.32 μM, 
respectively. In addition to low cytotoxicity values and 
non-interference with glutathione reductase of humans, the 
study analyzed the interactions between the compounds 
with the targets through docking, confirming the key 
residue of Cys166 to GAPDH and Leu399 to TR as 
essential for the activity.
In studies of Pieretti et al. (2013) they used 
derivatives of naphthoquinone (Figure 8) in screening 
FIGURE 6 - Derivate diarylideneketone that acts on the enzymes 
TIM/cruzipain in antitrypanosomal activity.
for new anti-trypanosomatids, of which an ED50 of 80 
nM was found. In their docking studies they showed 
that the most active compound, B6, fits the active site of 
the enzyme TbGAPDH, besides presenting the residue 
Cys166 as a key point for the activity. Another target was 
reported by Portela et al. (1996), of which reported the 
inhibition of derivatives naphthoquinones in inducing 
oxidative damage in trypanosomatids.
Dengue
Dengue fever is a disease caused by the dengue virus 
(DENV) by mosquito transmission by Aedes aegypti and 
Aedes albopictus (Stolp et al., 2015), which results in 
several symptoms ranging from mild fever to hemorrhagic 
dengue fever. The virus belongs to the family Flaviviridae 
and acts as the main cause of diseases arboviral (DENV-
1, DENV-2, DENV-3, and DENV-4) in tropical and 
subtropical regions (Sankarasubramanian, Pavithra, 
Kavitha, 2015), and new detection of DENV-5 (Mustafa 
et al., 2015), opening a new dilemma in disease control. 
A 2013 estimate indicated that 390 million dengue 
infections each year, of which 96 million (67-136 million) 
manifest clinically (with any severity of the disease). 
There is a discrepancy between the dengue data estimated 
by the academic groups and those reported to the WHO, 
due to the lack of resources and the capacity to effectively 
research dengue, in addition to the fact that in many 
countries reports only confirmed cases in the laboratory, 
representing a small share of the total number of cases 
(WHO, 2018b).
Among the drugs developed for DENV activity 
are flavonoids, with research reporting several antiviral 
FIGURE 8 - Derivative naphthoquinone that promotes the 
activity of anti-trypanosomatids.
FIGURE 7 - The hybrid derivative quinone–coumarin that targets 
the enzymes GAPDH and TR.
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activities. In studies of Qamar et al. (2014), 2200 
flavonoids (Figure 9) and docking analyzes of medicinal 
plants were performed on the NS1 protein block, 
calculating the possible active sites. The study resulted 
in 6 ligands, which showed strong interactions of 
the enzyme with the ligand, detecting the Asn-130 
glycosylation of the NS1 target as a key binding site for 
activity. 
Flavonoid activity for NS2B-NS3 enzymes has also 
been reported using molecular bioinformatics/docking 
tools, of which quercetin (Figure 10) has been shown to 
be the best inhibitor in the interactions with residues Asn 
152, Ala 164, Lys 74, Asn 167, Leu 149, and Gly 87, as 
well as stability with the targets NS2B-NS3 (Senthilvel 
et al., 2013). Sousa et al. (2015) also demonstrated the 
action of flavonoids in the antiviral action of dengue, with 
activities ranging from 15 to 44 µM. In this same study, 
the molecular docking with the enzyme NS2B-NS3 was 
performed, in which all inhibitors were observed to bind 
in a similar way to the receptor, with the best interaction 
with the quercetin molecule.
In another article published by Vicentti et al. (2015), 
it has also been described the discovery of dengue virus 
inhibitors by means of virtual screening of ChEMBL for 
inhibitors of the enzyme c-SRC (Figure 11), which may be 
capable of interacting with the NS5 enzyme of the dengue 
virus. The collected compounds had IC50 activities lower 
than 100 μΜ, comparable to dasatinib and saracatinib. In 
this study, molecular docking analyzes (for 3000 thousand 
compounds) showed NS5 enzyme selectivity indexes 
better than the standard compound, blocking the formation 
of the NS3-NS5 viral complex and the inhibition of kinases 
c-SRC/Fyn of the host. 
In the study carried out by Tambunan et al. (2011), 
a docking study with cyclic disulfide peptide ligands 
(Figure 12) in NS2B-NS3 enzymes for inhibition of virus 
growth was conducted. Among the ligands of the study, 
the compounds showed high affinities with the receptor, 
with formation of hydrogen bonds with Asp75 being the 
key link for the activity. 
In another study, Borowski et al. (2002) evaluated 
the antiviral activity of several nucleosides, benzimidazole 
FIGURE 9 - Flavonoid reported in the literature because it has 
activity towards the NS1 enzyme.
FIGURE 10 - Multi-target flavonoid that possessed an activity 
in the NS2B-NS3 complex.
FIGURE 11 - Inhibitor of the enzyme c-SRC, which also acts 
on the DENV NS5 protein.
FIGURE 12 - Cyclic disulfide peptide ligand multi-target that 
acts on the NS2B-NS3 enzymes.
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2-aminotiazoles (Figure 15) can act against the enzymes 
PARP-1 and BACE-1, with predictive activities that 
provided a basis for further development and structural 
optimization of novel potent inhibitors for the treatment 
of Alzheimer’s disease. 
In another study, 67 hybrid molecules were designed 
with indole (Figure 16), and that by means of screening 
only 13 hybrids were selected that were submitted to 
molecular docking analysis of the enzymes PLA2, LOX-5, 
COX-2, and cholinesterase A and B (Dileep et al., 2013). 
As a result, when calculating their interaction energies, 
they observed that 3 hybrid compounds had strong 
interactions with the study targets, with better energy 
values compared to standard reference drugs. 
In studies of Hui et al. (2014), they performed tests 
in silico and in vitro on various tacrine-phenothiazine 
derivatives (Figure 17) in the discovery of multitarget 
action. In their study they reported inhibitory compounds, 
with relevance to the compound T5, of the enzyme 
AChE, besides action of hyperphosphorylation of the 
enzyme tau and aggregation of beta amyloid. In another 
study in silico, Speck-Planche et al. (2013) analyzed 483 
FIGURE 14 - Derivative triazinone that acts simultaneously on 
the enzymes BACE-1 and GSK-3B.
FIGURE 15 - Derivative 2-aminotiazole that can act on PARP-1 
enzymes and BACE-1.
FIGURE 16 - Hybrid with an indole moiety reported to act on 
the enzymes PLA2, LOX-5, COX-2, and cholinesterase A and B.
and ribose analogs with benzotriazole derivatives 
(Figure 13). These compounds showed considerable 
inhibition of the enzymes NTPase with IC50 50 µM and 
helicase at 3 µM.
NEURODEGENERATIVE DISEASES
Neurodegenerative diseases have several problems 
in the medical field that need to be addressed because 
of their sharing of multifactorial mechanisms of action. 
Among the existing neurodegenerative diseases, 
we can mention: Alzheimer (AD), Parkinson (PD), 
Huntington (HD), and amyotrophic lateral sclerosis (ALS) 
(Lansbury, 2004). However, such diseases present clinical 
manifestations and mechanisms of action that converge 
among themselves, which involve the unfolding and 
aggregation of proteins, oxidative stress and the formation 
of free radicals, metallic dishomatosis, mitochondrial 
dysfunction, and phosphorylation impairment. Currently 
the term multitarget has been intensifying and solidifying 
studies in this area as a way to control the multiple targets 
responsible for the pathogenesis of the disease, known as 
Multi-Target Directed Ligands (MTDL) (Bishop, Sham, 
2000; Morphy, Rankovic, 2007). 
For example, Prati et al. (2015) described the 
triazinones (Figure 14) as multitarget molecules that may 
represent a promising starting point in developing lead 
compounds for Alzheimer disease. In the study it was 
reported that the triazinones can modulate the enzymes 
BACE-1 and GSK-3B simultaneously, with IC50 values 
ranging from 18–0.01 μM on BACE-1 and 14–0.78 
μM on GSK-3B. In studying the interactions through 
the molecular docking study of the compounds with 
both enzymes, they found that the compounds, mainly 
compound 3, acquired dual-target profiles because they 
had strong interactions with both enzymes tested.
Considering the deregulation of some specific 
proteins in Alzheimer disease, Zhang et al. (2012) 
conducted studies in silico and found that derivatives 
FIGURE 13 - Benzimidazole derivative targeting NTPase and 
helicase enzymes.
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compounds from a database and performed multi-target 
QSAR analyses using an LDA model. In their study, the 
descriptors were computed, and a model was constructed 
for the prediction of inhibitors that could act on proteins 
amyloid-A4 (ABPP), GSK-3α, GSK-3β, MAO-B, and 
PS-1, all associated with Alzheimer disease.
In another study, a series of phenyl pyrazole 
derivatives (Figure 18) have been reported as inhibitors of 
acetylcholinesterase (AChE) and of monoamine oxidase 
A and B (MAO-A and B), with selective activities in the 
micro and nanomolar range of 0.06 μM to AChE and 2.69 
μM to MAO A and B (Kumar et al., 2013). In the same 
study, structure-activity relationships were analyzed, 
where they showed that the derivatives with the chlorine 
moiety were more effective, but the molecular modeling 
data did not present in agreement with the experimental 
study, from which the strongest interactions occurred with 
the acetylcholinesterase. 
Among the natural compounds reported in the 
literature are baicalin (Figure 19), a flavonoid obtained 
from the plant Scutellaria baicalensis Georgi, which 
causes decreased activity of ONOO- and, successively, 
neurotoxicity (Xu et al., 2013) at a concentration of 
10–50 mg/kg. For the same compound, studies of its 
activity in the inhibition of the calcium influx NMDA 
and 5-lipoxigenase, which leads to a decrease in neuronal 
death, was found at a concentration of 1–5 μM (Ge et al., 
2007). In the studies carried out by Gao et al. (2013) in 
silico analysis of molecular docking and structure-based 
pharmacophore was performed, searching for activity 
against COMT and MAO-B proteins. In this study it was 
seen that baicalin has the potential to modulate the activity 
of the two proteins mentioned and guaranteed a protective 
role in neurotoxicity, but the activity of baicalin against 
the NMDA enzyme did not exhibit an inhibitory effect in 
a [3H] MK-801 binding study. 
Another natural  compound is  huperzine A 
(Figure 20), an alkaloid isolated from Huperzia serrata, 
which acts as an inhibitor of acetilcolinesterase (AChE) (Li 
et al., 2008; Wang, Yan, Tang, 2006), without promoting 
toxicity. Molecular docking studies demonstrated a higher 
specificity of interaction between AChE and huperzine A, 
of which the aromatic ring portion of the compound was 
responsible for the activity by binding to the aminophenol 
moiety of the enzyme, thereby promoting its inhibition 
(Yan et al., 2009). Inhibitory activities have also been 
reported for ROS enzymes at 0.1 mg/kg (Zheng, Zhang, 
Tang, 2008), NF-ḳB at 0.1 mg/kg (Wang et al., 2008), 
and NMDA 10 nM in calcium influx during neurotoxicity 
mechanisms (Gordon et al., 2001).
Honokiol (Figure 21) is derived from Magnolia 
grandiflora and has been shown to be a compound 
with multi-target characteristics acting in the blockade 
of the translocation of NF-ḳB and by inhibiting NO 
production in glial cells at a concentration of 0.7–70 
FIGURE 17 - Tacrine-phenothiazine derivative with multitarget 
action against the enzymes AChE, tau, amyloid-A4 (ABPP), 
GSK-3α, GSK-3β, MAO-B, and PS-1.
FIGURE 18 - Phenylpyrazole derivative that can inhibit the 
enzymes AChE and MAO A and B.
FIGURE 19 - Baicalin, which has been reported in the literature 
to inhibit NMDA, 5-lipoxygenase, COMT, and MAO-B 
enzymes.
FIGURE 20 - Huperzine A acts as a multitarget by inhibition of 
AChE, ROS, NF-ḳB, and NMDA enzymes.
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mg/kg (Zhang et al., 2013). In addition to these targets, 
Cui et al. (2007) revealed the inhibition of NMDA 
mediated neurotoxicity. Honokiol has also been reported 
to stimulate the expression of ApoE, ABCA1, and 
ABCG1 in cells (Jung et al., 2010; Kotani et al., 2012). 
Besides these targets, it has also been reported to have 
activity against Aβ through the regulation of autophagy, 
decreasing the phosphorylation of Akt and mTOR, and 
inhibiting γ-secretase through the negative regulation 
of the expression of the complex γ-secretase (Kaushik 
et al., 2012; Chang et al., 2013). In studies by Saeed 
et al. (2014) in silico molecular docking studies were 
investigated with the AKT kinase domain enzymes, 
STAT3 DNA binding domain, both mTOR complexes 
(mTORC1 and mTORC2), and both homologous 
MAPKKs (MEK1 and MEK2). In the study, it was seen 
that the compound bound to the same binding sites as the 
standard drugs erlotinib and gefitinib.
AIDS
Studies on the human immunodeficiency virus 
(HIV-1), which causes acquired immunodeficiency 
syndrome (AIDS), have been of great interest to the 
pharmaceutical industry due to the high incidence of 
cases of infection (Jorissen et al., 2009) and due to 
the appearance of drug resistant strains. The use of 
antiretroviral drugs with unique targets is no longer 
recommended for clinical use, as drug resistant strains 
have appeared. A combination of antiretrovirals targeting 
different viral targets is required for better suppression of 
viral growth (Johnston, Hoth, 1993).
Liu et al. (2010) performed a multitarget quantitative 
structure-activity relationship (QSAR) study with human 
immunodeficiency virus (HIV-1), using a protease, 
integrase, and reverse transcriptase regression model. 
In this study, we presented a way to identify and even 
design inhibitors that couple to multiple targets in an 
efficient way, which determines the importance of this 
study, since the drugs used in the therapy concentrate, 
FIGURE 21 - Honokiol acts with multi-targeting activity by 
inhibiting the enzymes NF-ḳB, NMDA, γ-secretase, STAT3, 
mTORC1 and mTORC2, and MEK1 and MEK2.
in the majority, on the inhibition of only a single target. 
The multi-target QSAR model was based on multi-task 
learning, where the three sets of target data with different 
percentages in training (10%, 30%, 50%, 70%, and 90% 
of the whole data) were used. Such a model was applied 
for the prediction of affinity. From the results found, a 
superiority of the multitarget QSAR under the single-target 
was observed, since they can take advantage (this can 
be seen more clearly, in small datasets) of the multi-task 
learning synergy and can take advantage of the synergy 
among tasks when the label data on each single task are 
insufficient.
Thus, the authors conclude that multitarget virtual 
screening with a multi-task learning paradigm can facilitate 
the identification of leads for HIV-1 inhibitors, besides 
reducing time, effort, and cost to obtain compounds to be 
evaluated for their activity and efficacy in the treatment 
of AIDS.
In a study carried out by Speck-Planche et al. (2012) 
(C-C chemokine receptor type 2, C-C chemokine receptor 
type 5, C-X-C chemokine receptor type 2, C-C chemokine 
receptor type 4, retroviral aspartyl protease, reverse 
transcriptase, retroviral integrase), two mt-QSAR models 
were developed starting from a large and heterogeneous 
bank of compounds where for each protein a cut-off value 
of inhibitory activity was considered. For the first model, 
a linear discriminant analysis (mt-QSAR-LDA) was 
used by the use of fragments-based descriptors, the best 
model presented 16 descriptors (Equation 1). Artificial 
neural networks (mt-QSAR-ANN) were used for the 
development of the second model, with the best model 
presenting the following RBF profile 11: 11-293-1: 1.
AHIV-IP = –0.607 (R=Ct) – 1.843 (ArOCON) + 1.299 (RCO)
+ 0.666 (ArCO) – 1.426 (RC=N) + 1.597 (ArCN)
+ 0.722 (Pyrld) + 0.700(C - 027) + 0.769 (C-041)
– 0.306 (O-060) + 0.538 (N-075) + 0.484 (F-084)
+ 4.427 x 10-4 µ5(Std) – 0.021 avg µ3(Ab-sumB20)
+ 0.414 difµ1(Gas) – 1.286 x 10-5 dif µ9 (Ab-R2) – 2.250
N=1341    λ=0.381    X2=1284.93    F(16, 1324) = 134.54     
p < 0.001   (1)
It was observed that the generated models correctly 
classified more than 90% of active and inactive compounds 
for the training and prediction. Thus, new molecules 
designed from fragments with positive contributions 
were analyzed in the models produced and were correctly 
predicted as possible anti-HIV agents, where for the 
mt-QSAR-LDA model the probability of all molecules 
being anti-HIV was high. The results of the forecasts for 
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the mt-QSAR-ANN model confirmed that in 40 of the 
42 cases (95.24%), the forecast could be correct. This 
fact demonstrates that all new molecules (especially 
compounds of MTI-2 to MTI-5 (Figure 22)) can be 
considered possible anti-HIV agents acting on the cited 
targets.
In addition, a new model of linear regression based 
on the similarity of the genetic function was developed 
by Edache et al. (2016), who performed a multi-target 
quantitative structure-activity relationship (mt-QSAR) 
study with immunodeficiency virus and using data sets of 
inhibitors (containing 150 compounds with well-defined 
activity) (Edache, Uzairu, Abechi (2015), Luco, Ferretti 
(1997)), aimed at integrase and reverse transcriptase.
These compounds were designed and minimized by 
the Spartan’14 (2013) version 1.1.2 (Wavefunction, 2013) 
using molecular mechanics (MMFF) and had descriptors 
calculated by PaDEL-Descriptors version 2.18 (885 
in total) (Yap, 2011). The most significant models are 
illustrated below:
Model 1:
PIC50 = 3.08172 (+/−0.52134) + 3.09393 (+/−0.52028) 
ATSc3 + 28.05602 (+/−3.2988) SCH − 3 − 34.91622 
(+/−3.30279) VCH − 7 − 13.37449 (+/−1.35611) VC − 5 
+ 3.67308 (+/−0.18491) VPC − 5 − 0.76154 (+/−0.08721) 
nHBd − 2.48376 (+/−0.49227) nddssS − 0.24588 
(+/−0.04857) minHBint5 (2)
N = 120, LOF = 1.7850, R = 0.9658, R2train = 0.9329, R2adj = 
0.9280, Q2cv= 0.9065, F − test = 192.7484, SEE = 0.6557, 
Q = 1.4729, PRESS = 66.4307, SDEP = 0.7440, r2test = 
0.8929, r20 = 0.8891, r’20= 0.8911
FIGURE 22 - Four best molecules suggested as possible versatile anti-HIV agents (MTI-2 to MTI-5, numbered 1–4, respectively).
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Model 2:
PIC50 = 3.35843 (+/− 0.50132) + 3.45359 (+/− 0.5738) 
ATSc3 + 26.16473 (+/− 3.20745) SCH − 3 − 32.26124 
(+/− 3.02354) VCH − 7 − 13.26959 (+/− 1.37737) VC − 5 
+ 3.57781(+/− 0.18586) VCP − 5 − 0.43222(+/−0.08688) 
nHBd  −  0 . 18283  (+ /−0 .03768 )  maxHBin t5  + 
0.56005(+/−0.10593) gmin (3)
N =120, LOF = 1.8483, R = 0.9648, R2train = 0.9305, R2adj 
= 0.9255, Q2cv = 0.9108, F − test = 185.6753, SEE = 
0.6672, Q = 1.4460, PRESS = 63.3978, SDEP =0.7269, 
r2test = 0.9039, r20 = 0.9024, r’20= 0.901
According to the authors, the constructed models 
were robust and satisfactory, and the descriptors could 
explain the characteristics responsible for inhibition of HIV.
Zhang et al. (2006) performed a double mutant 
reverse transcriptase (K103N) and wild type (WT) inhibitor 
assay. The molecular docking and 3D-QSAR approaches 
were applied to a set of twenty-five 4,1-benzoxazepinone 
efavirenz analogs (SUSTIVA®) (Figure 23). The CoMFA 
and CoMSIA models have reasonably high r2cv values 
ranging from 0.656 to 0.834 for type WT and K103N, 
respectively. From the validation, it was concluded that 
both models are predictive and extrapolative. In more 
detail, the authors reported that CoMFA analysis has 
shown that steric interactions are the main inhibitory factor 
for WT. However, CoMSIA analysis demonstrated that 
the donor effects of steric, electrostatic, and hydrogenated 
bonds present the same contributions for the binding of 
inhibitors to K103N.
Based on this study, it was possible to better 
understand the interaction of the compounds evaluated 
with the WT and K103N reverse transcriptase, favoring 
the choice of a pharmacophore for the compounds and the 
design of new double inhibitors.
CANCER
Prostate cancer (PC) is the most common diagnosis 
of cancer among men and the second leading cause of 
cancer death. Several forms of treatment for the local 
tumor have been widely used (Arshad et al., 2017). 
However, when invasion occurs to other organs, 
conventional treatment is not always effective. The search 
for potent anti-PC agents is a challenge. In recent years, 
several computer-aided design methodologies (CADD) 
have contributed to the search for compounds with anti-
PC activity. However, these methodologies do not always 
have advantages, as they generally reach only one PC 
cell line or only one target as the PC-associated protein. 
In this sense, Speck-Planche et al. (2011), developed the 
first multi-target approach for the planning and prediction 
of anti-PC agents against several cell lines. This planning 
represents a fragment-based QSAR model using a 
heterogeneous database of compounds for the efficient and 
rapid extraction of substructures responsible for anti-PC 
activity depending on the type of PC cell line.
The fragmented QSAR model, according to the 
authors, is expressed in functional group counting 
descriptors (CGF),  which contain fragmentary 
characteristics of specific functional groups in a molecule 
and is calculated from the molecular composition and 
atom of connectivity. A set of 816 compounds with anti-
PC activity against four PC cell lines (CWR22R, LAPC4, 
LNCaP, and PC-3) were analyzed and the CGFs calculated 
using DRAGON v5.3.11. The spectral moments of the 
weighted binding adjacency matrix (TOPS-MODE of 
order 1 to 15) were calculated using MODESLAB v1.5.37. 
Linear Discriminant Analysis (LDA) was used to construct 
the classifier model.
The results showed that the number of variables did 
not significantly improve the quality of the model, whereas 
a decrease in the number of variables improved the quality 
and predictive ability. The sensitivity of the model was 
88.36% and the specificity was 94.06% in the series 
formation, to an accuracy of 91.28%. The sensitivity of the 
model in prediction series was 89.81% and the specificity 
was 92.92%, with precision of 91.39%. The ROC curves 
were 0.97 for both training and forecast series. In this 
sense, six molecules were considered favorable in relation 
to fragments for anti-PC activity (Figure 24).
Another study that sought potent anti-PC multitarget 
agents was carried out by Ban et al. (2017). The study 
integrated a number of molecular modeling techniques 
available with a series of experimental tools to successfully 
develop a new class of potent selective androgen receptor 
inhibitors with a new mode of action (Ban et al., 2017). 
The differential of this study was the favorable screening 
of regions ideal for drug planning. Because human 
androgen (RA) receptors are considered master regulators 
for prostate cancer and the cancer cells often become 
FIGURE 23 - Structure of efavirenz.
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resistant to the drugs used to inhibit these receptors, the 
researchers in this study developed AR-driven drugs with 
a completely new mode of action. To do this, they used 
molecular modeling techniques that allow the exploration 
of all viable small molecule binding sites on the surface 
of RA. They used the Molecular Operating Environment 
(MOE), a software package 27 used for many modeling 
tasks, and a protein database (APO) to examine deposited 
structures of the ligand binding domain (LBD) of the 
AR (ID PDB: 2PIO), as well as the DNA binding of the 
receptor domain (DBD) (ID PBR 1R4I). 
Conventional molecular graphics tools such as MOE 
and Maestro were used to explore those in RA to identify 
mutations and to verify conserved and non-conserved 
regions that outweigh drug resistance for the planning of 
new drugs. In this article, we present the structure-based 
virtual screening (SBVS) using GLIDE (Friesner et al., 
2004, Halgren et al., 2004, Friesner et al., 2006) and 
ligand-based virtual classification through QSAR 4D that 
accurately describes and quantifies important structural 
aspects involved in mutant drug interactions (Paul et al., 
2016). The most active compound, 4- (4-phenylthiazol-2-
yl) -morpholine (vpc14228) (Figure 25) demonstrated an 
IC50 of ~0.5 μM in GFP assays and for PSA was considered 
by the study to be the most promising candidate for more 
detailed evaluation of a multi-target effect. 
Another important step was lead optimization, 
which represents another critical step in a drug in 
the discovery process. The main goal of successful 
optimization of a lead is to turn a prospective compound 
into a clinical candidate through iterative cycles of 
CADD-assisted design, medicinal chemistry (Medchem), 
and experimental evaluation. To help develop a suitable 
synthetic strategy, they used the ADMET Predictor 7.2 
software (Steinbrecher, 2015). Thirty-four analogs of 
vpc14228 have been synthesized wherein the phenyl 
ring has been substituted by heterocycles or modified 
with several substituents. Of the compounds developed, 
21 demonstrated sufficient anti-RA activity (eGFP 
IC50 < 10 μM), where six of them exceeded the value 
of vpc14228 and the synthetic analog vpc14449 with 
2,4-dibromoimidazole showing a modest improvement 
in potency over vpc14228.
In general, CADD techniques and methodologies 
for the development of multi-target compounds as 
FIGURE 24 - Molecules considered favorable in relation to fragments for anti-PC activity.
FIGURE 25 - Structure of the compound 4-(4-phenylthiazol-2-
yl)-morpholine (vpc14228).
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FIGURE 26 - Structure of the compound PubChem ID 
47037197.
FIGURE 27 - Compound 7r reported in the literature for 
inhibiting the enzymes VEGFR-2 and SRC.
anticancer agents are targeted at crucial targets in tumor 
transformation and progression and not for a particular 
type of cancer. There are some types of cancer that are 
a specific case, but cancer is considered a multifactorial 
disease. For example, there is a need to inhibit or reduce 
the action of side effects on various organs and also reduce 
drug resistance by various targets. 
A multitarget agent has been increasingly explored 
as targeted anticancer agents (Pilpel, Sudarsanam, Church, 
2001; Muller, 2004; Keith, Borisy, Stockwell, 2005; 
Christopher, Overall, 2006; Sergina et al., 2007) to achieve 
therapeutic efficacy. Several successful multi-target drugs 
in cancer treatment are sunitinib against PDGFR and 
VEGFR, dasatinib against ABL and SRC, and lapatinib 
against EGFR and HER2 (Gill et al., 2007; Krug, Hilgerot, 
2008).
Ma et al. (2010) rate a virtual tracing method using 
vector support machines (SVM) for their performance 
in the search of dual inhibitors using large library 
partnerships in the PubChem Database and the active 
agents of the MDR database. The SVM of each of the six 
anticancer targets EGFR, FGFR, VEGFR, PDGFR, SRC, 
and LCK kinases. Double inhibitor recovery rates were 
40.9% for EGFR-FGFR, 52.6% for VEGFR-LCK, 38.3% 
for PDGFR-SRC, and 48.2% for SRC-LCK, respectively. 
Thus, combinatorial SVMs show reasonably good ability 
to selectively identify multi-target agents.
Marzaro et al. (2011) reported the importance of 
tyrosine kinases (TK) as important targets in cancer 
development and explored potential strategies to inhibit 
these receptors. The work focuses on relevancy for the 
development of multi-target drugs, since most inhibitors 
are designed to be selective against a single TK or at the 
most two. Like Ma et al. (2010), Marzaro (2011) also 
used SMV to identify multitarget drugs. A set of data 
for generation of mtc-QSAR models were constructed. 
The structure and biological data of 1300 consisting of 
TCT, 3 cytoplasmic TKs (ABL, LCK, and SRC), and 
5 TK receptors (EGFR, FGFR1, KDR, PDGFRβ, and 
VEGFR-1). The compounds were tested against more 
than one TK. To evaluate the efficacy of the prediction, the 
selected models were asked to classify a set of 13 known 
compounds. The results showed a high degree of structural 
variability and presented a wide range of activities (from 3 
pM to up to 100 µM). In addition, five QSAR multitarget 
models for the classification of TKIs was developed. Due 
to the good accuracy of the model, this model may be 
useful for finding new inhibitors of kinases.
Li et al. (2011) investigated multi-target anticancer 
inhibitors for EGFR, VEGFR-2, and PDGFR. In this 
study, two virtual selection methods were selected for the 
choice of compounds to be tested as potent multi-target 
inhibitors, vector support machines (SVM) and molecular 
coupling. The compounds were withdrawn from the 
PubChem database and through virtual screening, three 
compounds derived from benzimidazole were identified 
as potent inhibitors. A series of compounds derived 
from benzimidazole identified in the virtual screening 
were synthesized and evaluated for biological activity. 
Specifically, compound 47037197 (Figure 26) identified in 
the screen showed inhibition against two receptors, EGFR 
and VEGFR. All benzimidazole derivative compounds 
that were synthesized showed anticancer activity. In this 
way, the study contributed to discover a new class of 
anticancer compounds.
Several other researches have also investigated 
receptor kinases as potent targets for the discovery and 
design of multi-target agents. Luan et al. (2011) analyzed 
a series of 21 acridine derivatives, which were synthesized 
and evaluated for their antiproliferative activity against 
K562, HepG-2, and MCF-7 cells. The molecular docking 
study as well as the results of inhibition of kinase in vitro 
assays indicated that compound 7r (Figure 27) may be a 
potent inhibitor of VEGFR-2 and SRC. They have also 
suggested that acridine, which has been used historically 
to inhibit topoisomerases, is a potentially interesting 
compound for inhibiting receptor kinases.
Other targets have also been cited in the literature as 
important strategies in the rational planning of multi-target 
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drugs for cancer treatment. Ning et al. (2015) has found 
from literature data that the inhibitor pacpirinib (SB1518) 
of JAK2 is reported to exert cytotoxic effects against 
cell lines bearing mutations JAK2v617f and FLT3-ITD. 
Anchorage studies showed that SB1317 binds to FLT3 
and JAK2 through the hydrogen bonding interactions 
with residues (Cys694 to FLT3 and Leu932 to JAK2) in 
the hinge region. It is known that HDAC interacts with 
FLT3 and JAK2; Ning et al., (2015) proposed structural 
modifications in HDAC inhibitors in order to inhibit the 
complex without compromising binding between FLT3 
and JAK2. Docking studies were conducted to identify 
the best interactions between targets and compounds. 
This was the first study to explore the design, synthesis, 
and evaluation of a single chemical entity that can 
simultaneously inhibit HDAC, FLT3, and JAK2. Thus, 
a number of target compounds have been carefully 
constructed by combining these structural features based 
on SB1317 and SB1518 macrocycle models. Most of these 
macrocycles have been shown to exhibit potent inhibition 
of HDAC as well as inhibition of FLT3 and JAK2. The 
research suggests that compound 32 (Figure 28) is the 
newest multi-targeting agent for HDAC, FLT3, and JAK2.
Schmidt et al. (2015) also investigated another class 
of inhibitors, the G protein-coupled receptors (GPRC). 
GPRCs are often responsible for signal transduction and 
are involved in several pathologies such as cancer. Thus, 
they proposed to prospectively identify ligands for two 
proteins through the fitting and predict their binding 
pattern. Despite the study using common computational 
techniques, the way they were applied reflects their 
differential in the search for multi-target drugs. The 
authors verified from the literature that the chemokine 
receptors CXCR3 and CXCR4 have a synergistic 
effect, which means that simultaneous blocking of both 
receptors could have a superior pharmacological effect 
compared to inhibition of any receptor. The ChEMBL 
database (version 17) recorded 858 and 484 binders 
tested against CXCR3 and CXCR4, respectively. Several 
resources were used in the study, among them, virtual 
screening based on structure, molecular docking, and 
molecular modeling by homology, among others. After 
inspecting the best anchored poses, four compounds were 
predicted to bind to both selected receptors. However, 
two of these four, compounds a and b (Figure 29), 
were considered active in both receptors according to 
the assays performed. Thus, the studied presented new 
CXCR3-CXCR4 double modulators that may aid in 
understanding the mechanisms of polypharmacological 
inhibition of these receptors.
Espinoza-Fonseca (2005) also studied other rather 
interesting targets for cancer, the tumor suppressor protein 
p53 and its negative regulator MDM2. p53 is responsible 
for the response to a range of cell lesions and is one of 
the main mediators of cell cycle arrest and the activation 
of apoptosis (Vogelstein, Lane, Levine, 2000). The 
aim of this study was to demonstrate that RITA, a drug 
originally found to bind to the p53 tumor suppressor, 
is also capable of binding MDM2-p53 transactivation, 
increasing its efficacy and making it a standard compound 
for cancer drug design. In using molecular docking, the 
authors discovered that RITA binds preferentially to the 
MDM2-p53 transactivation domain binding cleft. Thus, 
RITA was considered a multi-target compound for MDM2 
and p53 and a possible standard compound for the rational 
planning of multi-target and anticancer drugs.
FIGURE 28 - Structure of compound 32, the most active 
inhibitor against HDAC, FLT3, and JAK2.
FIGURE 29 - Structures of compounds a and b, inhibitors of the CXCR3-CXCR4 complex.
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New docking strategies to show target binding were 
tested and validated by Szelag et al. (2015). The study 
sought current strategies for modeling and selecting STAT 
inhibitors (signal transducer and activator of transcription) 
based on SH2. SH2 is a highly conserved domain that 
interacts with phosphotyrosine motifs for specific STAT 
receptor contacts and STAT dimerization, mediating a 
series of responses that when abnormal, implicate in the 
development of cancer and inflammation. Although a 
number of small molecules are known, many of them are 
not STAT3, specific from a six-membered family (STAT1, 
STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6). 
The study generated 3D structure models for all 
human STATs through homology modeling and performed 
coupling to obtain more information on the STAT-SH2 
cross-linking specificity of a previously identified STAT3 
inhibitor selection. The comparative affinity value of 
STAT and the variation of ligand binding pose were the 
criteria for the selection of inhibitors specific for STAT3 
as a new tool for virtual verification and validation. The 
ligand-based approach was used to generate a protomol 
molecular probe which is a 3D representation of the 
active site to which the ligands are combined, in this case 
in the STAT-SH2 region corresponding to the selected 
sub-pockets. The results showed that the affinity values 
of the STAT3 binding were the highest for the natural 
compounds: Cucurbitacin Q> Curcumin> Cucurbitacin 
E (9.08, 7.89, 7.49, respectively). Only the natural 
compounds cucurbitacin Q (for STAT2 and STAT5A) 
and Curcumin (for STAT5A) exhibited a certain degree 
of specificity for STAT3.
Yousuf et al. (2017) conducted a study based on 
virtual screening, molecular docking, and ADMET 
properties to propose new multitarget inhibitors for breast 
cancer. In this study initially ~3 million compounds were 
extracted from different databases, such as E-molecule 
databases and chemical companies including Pub-Chem 
and Active ZINC. All of the compounds extracted from 
these databases were submitted to different filters (LRo5, 
drug likeness, PK filters) to identify anti-breast cancer 
compounds, selecting the best 66,832 compounds. These 
compounds were subjected to structure-based virtual 
screening (SBVS) against EGFR, HER2, and HSP90 
separately to identify multi-targeted compounds common 
among all these targets using the software AutodockVina. 
Getting 96 top virtual hits against EGFR, 114 top virtual 
hits against HER2, and 79 top virtual hits against HSP90. 
The ligands were also analyzed for their profile 
of absorption, distribution, metabolism, excretion, and 
toxicity (ADMET), which determined the ADMET 
efficiency of the drug. Potential hits that indicate good 
pharmacokinetic (PK) and pharmacodynamic (PD) 
properties have a better chance to be effective future 
drugs. The results of the current study concluded that five 
multi-targeted compounds (S-258282355, S-258012947, 
S-259417539, S-258002927, and S-259411474) 
(Figure 30) with high binding energies that range between 
−8.7 to −10.3 kcal/mol as well as a good ADMET profile 
against all three targets be taken into consideration, 
suggesting them as potential hits for drug development 
against breast cancer after testing through in vitro and in 
vivo experiments.
Zhou et al. (2017) used a computer-aided rational 
drug design approach that led to the synthesis and 
characterization of CS2164 (N-(2-aminophenyl)-6-[(7-
methoxy-4-quinolinyl)oxy]-1-naphthalenecarboxamide, 
Figure 31) and evaluated as a novel multi-kinase inhibitor 
through the in vitro studies and the molecular docking. 
CS2164 inhibited VEGFR2, Aurora B and CSF-
1R kinases with very high potency (IC50 = 7, 9 and 7 
nM, respectively). CS2164 also displayed inhibitory 
activities with single digital nanomolar IC50 against 
several angiogenesis-related kinases, including VEGFR1, 
VEGFR3, PDGFRa and c-Kit. The IC50 for PDGFRb 
inhibition was tested as 93 nM. CS2164 only showed 
moderate inhibitory activities (100 nM < IC50 < 500 nM) in 
4 kinases (c-RAF, DDR2, PLK1 and PLK3), little activity 
(IC50 > 500 nM) in 33 kinases, and almost no activity 
(IC50 > 10 µM) in over 120 kinases, including 76 GPCR 
and 8 ion channels tested. Thus, these results indicate that 
CS2164 is a novel small molecule inhibitor with selective 
and potent inhibitory activities in VEGFR/Aurora B/
CSF-1R kinases. Consequently, CS2164 displayed anti-
angiogenic activity through suppression of VEGFR/
PDGFR phosphorylation, inhibition of ligand-dependent 
cell proliferation and capillary tube formation, and 
prevention of vasculature formation in tumor tissues. The 
molecular docking studies showed that CS2164 interacts 
with each active ATP binding pocket of VEGFR2, aurora 
B and CSF-1R kinases, respectively. Thus, it is being 
considered a potential candidate for cancer therapy as a 
multitarget agent.
Yuan et al. (2017) have performed the synthesis of 
new compounds derived from olaparib’s hydroxycinnamic 
acid derivative (the first FDA approved PARP inhibitor, 
poly (ADP-ribose) polymerase for patients with ovarian 
cancer with BRCA mutations), as well as evaluated its 
anti-tumor activity in vitro on seven different human tumor 
cell lines including breast cancer (T47D, MCF-7, and 
MDA-MB-231), lung cancer (HCC827), cervical cancer 
(HeLa), leukemia (K562), and lymphoma (U937) cell lines 
using an MTT assay. 
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Based on the rational strategy of drug design, 
the hydroxamic acid derivatives of olaparib were 
constructed as partial inhibitors of PARP and HDAC. 
Four new hybrids were synthesized (Figure 32). These 
hybrid compounds showed potent inhibitory activities 
against PARP1/2 and HDAC1/6 with values of IC50 in 
the nanomolar range (between 2,53 and 912.50 nM). 
In addition, compound P1 exhibited broad spectrum 
antiproliferative activities against selected human cancer 
cell lines (between 0,22 and 8,65 µM). Especially, P1 
showed more potent activity than olaparib and SAHA 
against cancer cells MDA-MB-231, HCC1937, and Raji, 
and 4.1-fold less cytotoxicity compared to SAHA for 
normal MCF-10A cells. 
Another mechanistic study has indicated that P1 
can induce PARP cleavage and histone hyperacetylation, 
increase biomarker expression of c-H2AX DNA damage, 
decrease BRCA1 and RAD51 levels, and regulate tumor 
cell growth and apoptosis through mitochondrial cell 
modulation and pathways mediated by death receptors. 
Therefore, our study suggested that compounds targeting 
PARP and HDAC simultaneously may be a practical 
approach to multitarget cancer therapy.
The above docking results may further confirm 
the inhibitory potency of P1 and P2 against PARP and 
HDAC. Thus, dual PARP and HDAC inhibitors, and 
FIGURE 30 - Chemical structures of lead compounds: (a) S-258002927; (b) S-258012947; (c) S-258282355; (d) S-259411474; 
(e) S-259417539.
FIGURE 31 - Chemical structure of CS2164.
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P1/P2 represent promising lead compounds for further 
optimization to develop novel antitumor agents.
Mayank and Jaitak (2016) investigated in silico the 
anticancer potential of alkaloids. Alkaloids are natural 
molecules that can be developed as multi-targeting 
inhibitors of the hedgehog (Hh) pathway. The Hh pathway 
is a developmental pathway that plays an active role 
in various developmental processes, such as cell fate, 
proliferation, survival, and differentiation. Up-regulation 
of the Hh pathway was found to be significantly associated 
with multiple forms of cancers along with its involvement 
in CSC maintenance. 
The alkaloids that were chosen were previously 
reported to have significant anticancer potential and 
further exploration of them from a mechanistic prospective 
may provide us a good anticancer lead molecule. Forty-
five alkaloids were screened in this study. The screening 
performed with molecular docking resulted in five lead 
compounds: 1 emetine, 2 cortistatin, 3 solamargine, 4 
solasonine, and 5 tylophorine (Figure 33).
The in silico experimental data indicated that 
emetine and cortistatin have the ability to modulate the Hh 
pathway by binding to sonic hedgehog (Hh), smoothened 
(Smo), and Gli protein, involved in the maintenance of 
FIGURE 33 - Chemical structure of lead compounds: 1 emetine, 2 cortistatin, 3 solamargine, 4 solasonine, and 5 tylophorine.
FIGURE 32 - Synthesis of designed dual PARP and HDAC inhibitors P1-P4. 
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cancer stem cells (CSCs). Furthermore, solamargine, 
solasonine, and tylophorine also seems to be good lead 
molecules targeting towards CSCs by modulating the 
Hh pathway. In addition to solamargine and solasonine, 
other best lead molecules also showed an acceptable in 
silico ADME profile. The predicted lead molecules can be 
suitably modified to obtain multitargeting CSC targeting 
agents to get rid of associated resistance.
Singh and Bast (2015) performed studies to discover 
multi-target natural compounds for receptor tyrosine 
kinase inhibitors and biological evaluation of cancer cell 
lines by employing in silico and in vitro approaches. A 
dataset of 50 000 ligands were used in this study obtained 
from the Inter BioScreen natural compound library (IBS), 
and 68 anticancer natural compounds that have been 
reported in the published literature.
All selected natural compounds were docked 
with the X-ray crystal structure of the selected protein 
by employing GLIDE (Grid-based Ligand Docking 
with Energetics) Maestro 9.6. InterBioScreen natural 
compounds docked with each selected protein molecule 
by using GLIDE high throughput virtual screening. 
On the basis of Gscore, we select 20 compounds 
along with 68 anticancer compounds for GLIDE extra 
precision molecular docking. It was discovered in this 
study that the compound epigallocatechin gallate (EGCG) 
(Figure 34) yielded a magnificent Gscore with IGF1R 
(PDB; 1K3A) and VEGFIIR (PDB; 2OH4), and the 
protein–ligand interactions have been charted out.
In another study, Singh and Bast (2015b), utilizing 
the same workflow of screening for multitargeted 
compounds, performed multitargeted molecular docking 
of tyrosine kinase receptors (RTKs) against natural 
compounds with the aim of finding multiple potential 
target inhibitors of insulin, epidermal growth factor, and 
androgen receptor involved in the development of several 
types of cancer. The RTKs are trans-membrane receptors 
that regulate a number of cellular activities, including 
cell migration, adhesion, apoptosis, and cell proliferation. 
Overexpression or overactivity of RTKs has been reported 
in a diverse of cancers, including prostate, breast, lung, 
and ovarian cancers. 
To investigate the effect of natural compounds on 
cancer cell growth and apoptosis by using in silico and in 
vitro, a dataset of 50 000 ligands were used in this study 
obtained from the Inter BioScreen natural compound 
library (IBS), and 68 anticancer natural compounds 
that have been reported in the publish literature. In the 
present study, CID5281672 (myricetin) (Figure 35) 
showing a high Gscore for EGFR and IR as compared 
to their respective controls. Molecular docking results of 
EGFR (PDB, 1M17) and IR (PDB, 3ETA) against natural 
compounds revealed that myricetin had a better Gscore, 
−10.47 and −9.92 Kcal/mol, respectively. 
Singh and Bast (2014) aimed to find a natural 
product that can be developed as a suitable PI3K signaling 
pathway inhibitor by using molecular docking studies. In 
this study, PI3K signaling components PI3K, PDK1, Akt, 
and mTOR were chosen and 51 natural compounds along 
with 17 reference compounds were selected as ligands 
with the aid of a PubMed published literature search. 
Ligands were docked to protein molecules by using 
Maestro 9.3 (Schrödinger Inc.). 
Myricetin, quercetin, morin, luteolin, and emodin 
(Figure 36) had significantly better energy scores than 
previously reported PI3K pathway inhibitors. These 
compounds have the best docking free energy score 
against PDK1 and PI3K.
Chen and Chen (2010) carried out a study using 
cheminformatics tools for the design of dual inhibitors 
of heat shock protein 90 (HSP90) and human epidermal 
growth factor receptor 2 (HER2). HSP90 and HER2 are 
two key cancer markers actively involved in various signal 
pathways for the growth of cancer cells. 
In this study, 48 compounds were used for the training 
and additionally 12 compounds were used for the validation. 
FIGURE 35 - Chemical structure of CID5281672 (myricetin).
FIGURE 34 - Chemical structure of epigallocatechin gallate 
(EGCG).
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The inhibitory activity of these compounds for HER2 were 
obtained indirectly from the study of Llauger (Llauger et 
al., 2005; He et al., 2006). Through comparative molecular 
field analysis (CoMFA), comparative analyses of molecular 
similarity indexes (CoMSIA), and pharmacophase analysis 
it was possible to generate predictive models of the 
inhibitory activity of this protein. 
The results of the CoMFA model showed a highly 
predictive r2 value with 0.922 and 0.885 in HSP90 and 
HER2, respectively. In the CoMSIA model, the r2 values 
were 0.967 and 0.936 in HSP90 and HER2, respectively. 
The contour maps of both targets showed that there were 
similar regions of a bulky favored area. Based on these 
results, the key criteria for designing a dual-target inhibitor 
for HSP90 and HER2 should consider the steric disfavor 
region in HSP90 and the electronegative favor and the 
hydrogen bond donor favor regions in HER2.
Additionally, the Hypogen results for HER2 
showed high cost differences at 59.13 and an r-value 
as 0.909. At the C2 position of the benzene ring, the 
HER2 model favored steric bulkier substitutes more than 
HSP90. The Hypogen results for HSP90 also showed 
reliable values in cost difference, 85.82, and r-value, 
0.902. The first hypothesis maps of HER2 and HSP90 
contained the same features: one hydrophobic feature, 
one hydrogen bond donor feature, and two hydrogen 
bond acceptor features.
Although both receptors had similar hypotheses, the 
orientation of the pharmacophore features was distinctly 
different, especially for the hydrogen bond acceptor 
feature. Comparison of HER2 and HSP90 pharmacophores 
gave a RMSD of 2.002. These results suggest that the 
effective compounds should have similar structural 
features but can adapt different poses in HER2 and HSP90 
active sites. Overall, we investigated the significances of 
QSAR models and pharmacophore features for designing 
the HER2/HSP90 dual-targeted inhibitors.
CONCLUSIONS
 In this review we discussed the importance of 
multitarget compounds in the treatment of various 
diseases, which are highly effective when related to 
complex and multifactorial diseases. We verified during 
the course of our researches that the use of in silico 
methods in drug design emerges as an advantageous 
process, since this investigation presupposes better results 
with lower expenses, as well as performs screening for 
several receptors that can interact with the drug, allowing 
the validation of a greater number of activities that can be 
tested a posteriori. The multitarget therapies presented 
here for each disease qualify the chemical structure in the 
discovery of new targets, thus favoring the increase of 
activity against diseases.
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